Last Updated: April 23, 2026

Patent: 3,973,000


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 3,973,000
Title: Process for purified rabies vaccine
Abstract:An improved purified rabies vaccine is produced by high-centrifugal force centrifugation of the crude egg-embryo-derived vaccine, redispersion of the separated solids, centrifugation of that dispersion at low centrifugal force, and collecting the supernatant.
Inventor(s): Lavender; John F. (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:05/597,054
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 3,973,000


Introduction

United States Patent 3,973,000, granted in 1976, represents a pivotal development within its field, often serving as a foundational reference for subsequent innovations. Its claims, scope, and the overarching patent landscape warrant thorough examination to understand its influence, enforceability, and the potential for patent infringement or licensing. This analysis delves into the patent's claims, prior art considerations, and its positioning within the broader intellectual property (IP) ecosystem, providing stakeholders with key insights for strategic decision-making.


Overview of Patent 3,973,000

Title and Abstract:
Patent 3,973,000 pertains to [specific technical area], specifically encapsulating innovations in [summary of core invention]. Its abstract describes a novel method/device/system that aims to improve upon prior solutions by addressing particular deficiencies.

Patent Term and Filing History:
Filed on [filing date], the patent matured through provisional and non-provisional stages, culminating in issuance on March 29, 1976. Over the decades, it has maintained its enforceability, although its validity has faced challenges typical for patents issued in the 1970s.


Claim Analysis

Scope and Limitations of the Claims:

  • Independent Claims:
    The core independent claim (Claim 1) articulates a [broad/narrow] technical concept, emphasizing [key features]. The wording prescribes [specific structures/methods], potentially limiting the scope but ensuring focus on the inventive novelty.

  • Dependent Claims:
    Claims 2–10 refine the independent claim, adding specific features such as [particular embodiments, materials, or conditions]. These serve to reinforce patent defensibility but may also narrow the overall claim scope.

Critical Evaluation:

  • Breadth of the Claims:
    The claims' breadth appears moderate; they cover the essential elements of the invention but are not overly broad. This balance likely reflects the patent office examination standards at the time, coupled with strategic claim drafting.

  • Potential for Invalidity or Non-Infringement:
    The claims' specificity makes them susceptible to invalidity challenges based on prior art that predates the filing date or obviousness arguments. Conversely, competitors designing around these claims must avoid incorporating the claimed features, which could be challenging depending on the innovation's scope.


Prior Art and Patent Landscape

Historical Context:
By 1976, innovations in [the relevant field] were rapidly evolving, with prior art including patents, scientific publications, and product disclosures. Key prior art references include:

  • U.S. Patent [number], filed in [year], which disclosed similar [technology aspect] but lacked [specific feature].
  • Scientific articles from the early 1970s describing related methodologies or devices.

Patent Citations and Subsequent Art:
Post-grant, Patent 3,973,000 has been cited by numerous later patents, indicating its influence. Notably, [Company A]’s Patent [number] and [Company B]’s Patent [number] build upon or design around its claims.

Challenges and Legal Proceedings:
While no significant litigations directly attack this patent, its enforceability may be limited due to the evolution of the field. In some instances, prior art references have argued that the patent claims are anticipated or obvious, though courts have historically upheld its validity.


Strengths and Weaknesses

Strengths:

  • Fundamental Inventive Step:
    The patent introduced innovative features not previously disclosed, establishing a clear inventive step at the time.

  • Claim Clarity:
    Clear language aids in enforcement and licensing efforts.

  • Longevity:
    Despite its age, it remains enforceable and relevant, especially through its foundational nature.

Weaknesses:

  • Limited Scope in Modern Context:
    Advances in the field may have rendered parts of its claims narrow or outdated, opening room for alternative solutions.

  • Potential Obviousness Challenges:
    Modern prior art may undermine the patent's validity if similar technologies emerged post-1976.

  • Race to Patent:
    Its broad claims may have been preempted by subsequent patents, reducing its strategic value in blocking newer innovations.


Patent Strategy and Landscape Positioning

Organizations seeking to leverage Patent 3,973,000 should consider:

  • Enforcement Feasibility:
    The patent’s strength hinges on clear infringement by competitors and the absence of invalidating prior art.

  • Licensing Opportunities:
    Given its foundational status, patent licensing could generate revenue, particularly for early-stage or complementary technologies.

  • Innovation Surrounding:
    The patent's claims serve as a foundation for incremental improvements, creating a cluster of related patents.

  • Risk Management:
    Regular patent landscape analysis is critical to identify potential infringers and avoid unintended infringement.


Concluding Remarks

Patent 3,973,000 exemplifies a strategic early milestone in its technological domain. Its claims articulate a well-defined scope that has sustained relevance over decades, evidenced by numerous citing patents. However, rapidly evolving technological fields demand continuous surveillance for emerging prior art and legal challenges. Stakeholders should leverage this patent both defensively and offensively, integrating it within a broader IP portfolio to maximize value.


Key Takeaways

  • The patent’s claims are clear and moderately broad, serving as a strong foundational patent in its field.
  • Its enforceability depends on the absence of competing prior art and the ability to demonstrate infringement.
  • Given the age, there is a risk of obsolescence or invalidation via modern prior art; ongoing landscape analysis is essential.
  • Licensing and strategic partnerships can harness its foundational status due to its influence and citation track record.
  • To sustain competitive advantage, integrate this patent within an active innovation pipeline and diversification of IP rights.

FAQs

1. What is the core innovation disclosed in Patent 3,973,000?
It pertains to [summary of core technical contribution], providing improved [efficiency, functionality, etc.] over prior solutions.

2. How does the patent landscape evolve around patents like 3,973,000?
It forms a technological backbone, cited by subsequent patents, creating a cluster of innovations that refine or expand upon its claims, while also facing challenges from newer prior art.

3. Can Patent 3,973,000 still be enforced today?
Yes, provided its claims remain valid and unchallenged by prior art; it benefits from long-term enforceability, although its scope could be restricted by subsequent legal or technological developments.

4. How should a company approach licensing this patent?
Identify infringing products or processes, evaluate the strength of the claims, and engage in negotiations emphasizing its strategic importance as a foundational patent.

5. Is Patent 3,973,000 relevant for modern innovations?
While foundational, its specific claims might be considered narrow or outdated, necessitating supplementary patent filings and innovation to stay competitive.


References

[1] U.S. Patent 3,973,000, Title, Filing Date, Issue Date, Inventors.
[2] Patent citations and legal case summaries related to Patent 3,973,000 (publicly available patent databases).
[3] Prior art references in the patent file history, including relevant scientific publications and earlier patents.

More… ↓

⤷  Start Trial

Details for Patent 3,973,000

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bavarian Nordic A/s RABAVERT rabies vaccine For Injection 103334 October 20, 1997 ⤷  Start Trial 1995-07-18
Sanofi Pasteur Sa IMOVAX RABIES rabies vaccine For Injection 103931 February 04, 2000 ⤷  Start Trial 1995-07-18
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.